Knight Therapeutics | GUD - Equity Capital And Reserves


Knight Therapeutics reported CAD767.27M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acasti Pharma USD 62.82M 732K Sep/2025
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Aurora Cannabis CAD 536.36M 30.74M Dec/2025
Avita Medical AUD -16.65M 3.76M Dec/2025
Canopy Growth CAD 758.17M 22.16M Dec/2025
Cronos Group USD 1.07B 20.24M Mar/2026
Dianthus Therapeutics USD 1.2B 707.91M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
IQVIA Holdings USD 6.22B 282M Mar/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Organigram Holdings CAD 369.46M 20.33M Dec/2025
Organon & Co USD 903M 151M Mar/2026
Revvity USD 7.25B 125.54M Dec/2025
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Tilray USD 1.58B 39.08M Sep/2025
Viatris USD 14.66B 53.6M Mar/2026
Xeris Pharmaceuticals USD 13.01M 678K Mar/2026